Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis Qiaolei ZhangLixia ZhuXiujin Ye Original Article 02 June 2023 Pages: 2301 - 2308
Are accessory spleen screening and resection in refractory immune cytopenia an effective strategy or a waste of resources? Sergio Rodríguez-RodríguezJosé Miguel Álvarez-BlancoRoberta Demichelis-Gómez Original Article 13 July 2023 Pages: 2309 - 2315
The mTORC1 pathway participate in hyper-function of B cells in immune thrombocytopenia Yujiao XiangLu LiuYan Shi Original Article 08 July 2023 Pages: 2317 - 2327
Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease Ming ChenKenneth I. AtagaJames E. Bailey Original Article 14 July 2023 Pages: 2329 - 2342
Molecular insights into hereditary elliptocytosis and pyropoikilocytosis: NGS uncovers multiple potential candidate genes Durjoy K. ShomePriya DasRehab Helmy Original Article 04 July 2023 Pages: 2343 - 2351
Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation ShuQing WangXuan WangJian Li Original Article 31 July 2023 Pages: 2353 - 2364
Platelet is an unfavorable prognostic biomarker and associated with leukemia stem cells and immunomodulatory factors in acute myeloid leukemia Qing ZhangHaotian YanZhimin Zhai Original Article 15 July 2023 Pages: 2365 - 2373
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years Dongdong NiuYumei ZhaoJiayuan Wu Original Article 19 July 2023 Pages: 2375 - 2386
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis Chunxiao LiuXuewu ZhangWenjuan Yu Original Article 06 June 2023 Pages: 2387 - 2395
Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review Kai-Wen TanYi-Yan ZhuSheng-Li Xue Original Article 27 April 2023 Pages: 2397 - 2402
Positron emission tomography to detect bone marrow involvement for patients with follicular lymphoma: a systematic review and meta-analysis Yaxin ZhengJun LiuChen Tian Original Article 20 May 2023 Pages: 2403 - 2412
MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma Tianyu ZhuJiahao ShiYixiong Zhou Original Article 21 April 2023 Pages: 2413 - 2423
Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis Yangyang DingCheng SunZhimin Zhai Original Article 29 June 2023 Pages: 2425 - 2434
Clinical significance of plasma PD-L1+ exosomes in the management of diffuse large B cell lymphoma Peng XuJuan LiuYan Lin Original Article 10 May 2023 Pages: 2435 - 2444
Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series Mengze HuRong LiuRuihong Tang Original Article 20 May 2023 Pages: 2445 - 2457
Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study Jia-Ying LiXiao-Rong HouYe-Xiong Li Original Article Open access 12 June 2023 Pages: 2459 - 2469
Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV+ DLBCL-NOS: a Chinese cohort study Tong-Yao XingZi-Wen DuanWei Xu Original Article 10 May 2023 Pages: 2471 - 2481
ADAR1 polymorphisms contribute to increased susceptibility in pediatric acute lymphoblastic leukemia Mansi CaiXiaoping LiuXiaodan Liu Original Article 22 May 2023 Pages: 2483 - 2492
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma Yu AbeMakoto SasakiKenshi Suzuki Original Article Open access 21 June 2023 Pages: 2493 - 2504
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma Yu AbeMakoto SasakiKenshi Suzuki Correction Open access 11 July 2023 Pages: 2505 - 2505
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group Masuho SaburiKumi OshimaTransplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy Original Article 20 June 2023 Pages: 2507 - 2516
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction Vivian W.K. LiRita YimHarinder Gill Original Article 17 June 2023 Pages: 2517 - 2527
The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease Michael StadlerLothar HambachArnold Ganser Original Article Open access 25 July 2023 Pages: 2529 - 2542
Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) Alexander PohlmannEva BentgensChristoph Schliemann Original Article Open access 10 July 2023 Pages: 2543 - 2553
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary Kata HusiRoxána SzabóZsófia Miltényi Original Article Open access 10 July 2023 Pages: 2555 - 2563
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia Jin ZhaoLi MaXiaojing Guo Original Article 13 July 2023 Pages: 2565 - 2587
Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia Fan LinXinyu DongLanping Xu Original Article 13 July 2023 Pages: 2589 - 2598
Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients A. ChistoliniA. SerraoC. Santoro Original Article 21 July 2023 Pages: 2599 - 2605
Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies—a retrospective single-centre analysis of 200 cases Daniel GeßnerMirjeta BerishaEnrico Schalk Original Article Open access 25 April 2023 Pages: 2607 - 2616
Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Gerasimos TsilimidosSabine Blum Letter to the Editor 31 May 2023 Pages: 2619 - 2620
Mast cell leukemia associated with essential thrombocythemia: a type of MCL-AHN (MCL-AMN) Magda ZanelliFrancesca SanguedolceStefano Ascani Letter to the Editor 08 June 2023 Pages: 2621 - 2623
Paroxysmal nocturnal hemoglobinuria with ulcerative colitis Kenta HayashinoYuki FujiwaraYasushi Hiramatsu Letter to the Editor 20 June 2023 Pages: 2625 - 2626
The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Zhiyou YuYao YaoYing Wang Letter to the Editor 10 June 2023 Pages: 2627 - 2630
Characteristics and outcomes associated with venous thrombotic complications among patients with paroxysmal nocturnal hemoglobinuria Udhayvir S. GrewalSahith R. ThotamgariUsha Perepu Letter to the Editor 22 June 2023 Pages: 2631 - 2632
Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome Katarina Tomulic BrusichKazimir JuricicAna Boban Letter to the Editor 26 June 2023 Pages: 2633 - 2634
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma Victoria R. NacharAnthony J. PerissinottiTycel J. Phillips Letter to the Editor 09 June 2023 Pages: 2635 - 2637
Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation Takumi KondoMitsuko IguchiKensuke Kojima Letter to the Editor 23 June 2023 Pages: 2639 - 2640
Erythema nodosum as a manifestation of cytokine release syndrome after CAR T-cell therapy Delfim DuarteJosé Mário Mariz Letter to the Editor 24 June 2023 Pages: 2641 - 2642
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma Grzegorz S. NowakowskiDok Hyun YoonGilles Salles Correction Open access 11 July 2023 Pages: 2643 - 2644